It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
From candidate selection to clinic, we partner with you to design smart, scalable formulations built on solid-state insight, multidisciplinary expertise, and a shared commitment to scientific success.
At Sygnature Discovery, we specialize in solving the formulation barriers that stand between your molecule and successful clinical development.
Our technology-agnostic approach, grounded in expert solid-state characterization and data-driven decision-making, ensures every strategy is tailored to your compound’s properties and goals.
We seamlessly integrate solid form understanding into formulation design, aligning early decisions with downstream CMC expectations to reduce risk and accelerate your path to clinic. Whether you’re aiming for dose linearity in preclinical toxicology, improving crystallinity or solubility, or identifying the most stable polymorph to support manufacturability, our team brings the right expertise at the right time.
Working collaboratively across Process Chemistry and Scale-Up, DMPK, and Separation Science, we apply multidisciplinary insight to solve complex challenges and deliver robust, scalable solutions. Every decision is made with clarity, precision, and a shared commitment to scientific success.
Our Form & Formulation Solutions
We offer a comprehensive suite of services designed to accelerate your molecule’s journey from discovery to clinic while mitigating risk at every stage.
Solid Form Analysis
Understand and optimize your compound’s physicochemical properties.
Our Form & Formulation team provides the in sight and cross-functional context your CMC group needs to move confidently towards first-in-human studies. By aligning early solid form and formulation decisions with downstream CMC expectations, we help you anticipate challenges, reduce risk, and streamline progression to clinical manufacture.
Collaboration with CMC teams connects early learnings with future requirements. This integrated approach focuses on selecting the right drug-substance form, generating decision-quality characterization, and coordinating next steps for a smooth transition to clinical manufacture.
Why Choose Sygnature Discovery for CMC Support?
Sygnature Discovery delivers integrated CMC solutions that bridge early discovery with clinical development. Our team combines deep expertise in solid-state chemistry, preclinical formulation, and analytical sciences to help you:
• Select the optimal drug form
• Develop robust formulations
• Generate regulatory-ready data
Whether you’re navigating salt selection, crystallization development, or preparing for IND/IMPD submissions, our collaborative approach ensures your molecule is well-positioned for scale-up, clinical manufacture, and regulatory success.
Why Choose Sygnature Discovery for Form & Formulation Support?
We offer a truly multi-disciplinary development strategy, working seamlessly across Process Chemistry & Scale-Up, Drug Metabolism and Pharmacokinetics (DMPK), and Separation Science. This cross-functional collaboration ensures your molecule benefits from the right tools at the right time – solving even the toughest formulation challenges.
Our Form & Formulation team understands how solid form impacts formulation success. We work together to deliver solutions that helps your asset move swiftly towards patients in need.
Key Benefits
Our formulation strategy is built on expert solid-state characterization, chemistry, and DMPK knowledge brought together through a multidisciplinary approach. Every compound benefits from a bespoke, data-driven formulation strategy rather than a one-size-fits-all attitude.
End to end integrated early drug discovery
Seamless cross-functional collaboration and data flow across DMPK, solid form, formulation and wider drug discovery.
Amplified collective intelligence and insights
Individuals bring diverse experiences and skill sets driving efficiencies and faster problem solving.
Technology agnostic
We recommend formulations that are best suited to your molecule(s) properties and purpose such as toxicology, route considerations, overcoming liabilities like first pass metabolism or efflux.
Our team
Our Director of Form & Formulation
Sygnature Discovery prides itself on offering a unique, high-quality, distinctive and tailored integrated drug discovery service to our clients.
David Pearson, PhD
Director, Form and Formulation
In August 2021, Sygnature Discovery welcomed David Pearson as its Director of Form and Formulation, a position that perfectly aligns with his extensive expertise in solid form and formulation science, which spans over two decades. As a seasoned subject matter expert in solid form, David possesses a wealth of knowledge… Read More
Delve into the realm of targeted protein degradation and the critical role of formulation strategies in drug development. From overcoming dissolution limitations to optimizing stability and solubility, explore the key components that ensure your molecule’s clinical success. Sygnature Discovery offers comprehensive formulation support, bringing your degrader one step closer to achieving its full potential.
